ProCE Banner Activity

MRD Response and Prognosis With Venetoclax + Azacitidine in Patients With AML Ineligible for Intensive Induction Chemotherapy From the VIALE-A Trial

Slideset Download
Conference Coverage
Among patients with CR/CRi on venetoclax + azacitidine, achieving MRD <10-3 was associated with longer duration of response, event-free survival, and overall survival, regardless of when MRD negativity was attained.

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme